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Over a decade after the ﬁrst successful transcatheter
closure of a muscular ventricular septal defect (VSD)
back in 1987,1 the race began to develop a suitable
device for transcatheter closure of perimembranous
ventricular septal defects (PVSD). With the develop-
ment of braided Nitinol technology, the ﬁrst‐generation
devices showed early promise, although due to early
and late device complications associated with complete
atrioventricular block, the trip was delayed consider-
ably. However, over the past 7 years, considerable
progress has been made regarding device development.
Due to the chordal attachments of the atrioventricu-
lar valves, the curvilinear relationship of the inﬂow–
outﬂow septum, and in the majority of cases, close
relationship to the aortic valve and the AV node
conduction system, the ventricular septum is the most
complex anatomical structure interventionalists have to
deal with in the heart. By far, themost common location
of a congenital VSD is within the perimembranous
septum, as supported by the current article in this issue
of JOIC, where 90% of all VSD closure procedures
were done in PVSDs. By deﬁnition, a perimembranous
VSD is located just underneath the aortic valve (many
times impinging on the annulus of the aortic valve) with
the conduction system traversing just posterior‐inferior
to the defect itself. Due to this, transcatheter closure of
PVSDs has been, by far, the hardest “nut to crack.”
From earlier experiences, it became abundantly clear
that use of “off label” devices made for treatment of
other intracardiac defects (atrial septal defects, patent
ductus arteriousus) were not suitable for closure of
PVSDs. Difﬁculties encountered with impingement on
aortic valve leaﬂets, causing insufﬁciency, were
observed with the symmetric devices, and development
of early and late atrio‐ventricular block has been
observed with the ﬁrst generation of asymmetrical
devices.2,3 Part of the issue in the development of AV
block, particularly late‐onset AV block, relates to the
material used in making the device. Nitinol alloy
provides the foundation for all current VSD occluder
devices. One of the properties of Nitinol is that it
continues to expand, gradually over time, to its nominal
size. Therefore constant, and sometimes increasing,
pressure is put on the edges of the perimembranous
septum, which, in combination with the “abrasive”
properties of the device, could cause irreparable
damage to the AV conduction system. Newer‐genera-
tion devices have been developed that puts less tension
on the perimembranous septum, with early results
showing promise that development of AV block will be
minimized. One device, the Product For Medicine
(PFM) PVSD‐Li device, has not encountered complete
AV block to date.4
The authors in the current issue of the Journal of
Interventional Cardiology who wrote “A systematic
review of the efﬁcacy and safety of transcatheter device
closure of VSD’s” are to be commended for their
efforts.5 This is a considerable undertaking, and
although there are limitations in their approach that
they mention in their manuscript, they point to the
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challenges encountered in closing PVSDs. In just
focusing over the past decade, 6 devices have been
developed in an attempt to overcome the challenges.
The greatest challenge remains in closing PVSDs in
infants<6 kg. By far, the largest number of PVSDs that
are in need of surgical intervention are infants who are
in persistent heart failure weighing <6 kg. From the
STS database, over the past 5 years, between 210 and
235 patients >8 kg undergo surgical repair of their
PVSD every year in the United States. In contrast, more
than 10 that number undergo surgical closure of
PVSDs in infants <8 kg in the United States.
Unfortunately, over 98% of the patients reported in
the papers analyzed for this report were >8 kg in
weight. Clearly this remains a challenge in the area of
transcatheter closure of PVSDs.
So initial progress was made regarding transcatheter
closure of PVSDs, but unexpected complications
slowed the process down. The surgeons, with their
excellent outcomes, have set the bar high. Challenges
remain for the interventionalist to be sure, but recent
progress has lended encouragement that the majority of
children, and a greater number of infants, born with
hemodynamically signiﬁcant PVSDs will be able to
reliably undergo transcatheter device closure of their
defect.
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